IRIS UniCatt

Evoli Stampanoni-B, Amelia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.583
EU - Europa 3.799
AS - Asia 1.752
SA - Sud America 213
AF - Africa 53
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 10
Totale 10.430
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.527
DE - Germania 1.093
CN - Cina 740
SE - Svezia 710
SG - Singapore 553
UA - Ucraina 419
IT - Italia 386
FR - Francia 234
IE - Irlanda 226
PL - Polonia 168
GB - Regno Unito 158
BR - Brasile 146
ID - Indonesia 134
FI - Finlandia 112
IN - India 110
RU - Federazione Russa 99
TR - Turchia 61
BE - Belgio 46
JP - Giappone 36
CI - Costa d'Avorio 32
HK - Hong Kong 30
NL - Olanda 30
CA - Canada 23
RO - Romania 22
ES - Italia 20
AU - Australia 18
EC - Ecuador 18
CL - Cile 17
AT - Austria 16
IL - Israele 16
MX - Messico 16
CH - Svizzera 11
PE - Perù 11
AR - Argentina 9
CO - Colombia 7
CZ - Repubblica Ceca 7
IR - Iran 7
VN - Vietnam 7
BG - Bulgaria 6
BZ - Belize 6
GR - Grecia 6
KE - Kenya 6
KR - Corea 6
PK - Pakistan 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AZ - Azerbaigian 5
BD - Bangladesh 5
IQ - Iraq 5
PT - Portogallo 5
EU - Europa 4
LK - Sri Lanka 4
LT - Lituania 4
PR - Porto Rico 4
TH - Thailandia 4
AL - Albania 3
HU - Ungheria 3
LV - Lettonia 3
MA - Marocco 3
PH - Filippine 3
SA - Arabia Saudita 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
DK - Danimarca 2
DZ - Algeria 2
GA - Gabon 2
JO - Giordania 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MD - Moldavia 2
MU - Mauritius 2
MY - Malesia 2
NI - Nicaragua 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
A1 - Anonimo 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
CU - Cuba 1
CY - Cipro 1
DO - Repubblica Dominicana 1
JM - Giamaica 1
MK - Macedonia 1
MT - Malta 1
NG - Nigeria 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
TM - Turkmenistan 1
TN - Tunisia 1
UY - Uruguay 1
Totale 10.430
Salva come PNG Salva come JPEG
Città #
Chandler 891
Ashburn 404
Singapore 346
Jacksonville 281
San Mateo 230
Dublin 217
Wilmington 155
Ann Arbor 154
Warsaw 144
Nanjing 141
Jakarta 133
Houston 118
Dearborn 116
Woodbridge 114
New York 113
Cattolica 96
Boston 95
Princeton 71
Redwood City 69
Beijing 66
Milan 63
Lawrence 61
Moscow 59
Chicago 58
North Bergen 55
Nürnberg 53
Fairfield 49
Marseille 49
Seattle 49
Bremen 46
Izmir 45
Los Angeles 45
Nanchang 45
Fuzhou 42
Brussels 38
Hangzhou 37
Redmond 37
Abidjan 32
Shanghai 31
Mountain View 30
London 28
Hong Kong 27
Shenyang 27
Tianjin 26
Norwalk 25
Rome 25
Boardman 24
Hebei 24
Zhengzhou 24
Changsha 23
Düsseldorf 23
Nuremberg 21
Frankfurt am Main 20
Helsinki 20
Kunming 18
Leawood 16
Munich 16
Des Moines 15
Jiaxing 15
Millbury 15
Cambridge 14
São Paulo 14
University Park 14
Buffalo 13
Pune 12
Falls Church 11
Guangzhou 11
Philadelphia 11
Tokyo 11
Washington 11
Berlin 10
Fremont 10
Amsterdam 9
Dagenham 9
Málaga 9
Paris 9
San Jose 9
Bologna 8
Indiana 8
Kraków 8
Lauterbourg 8
Saint Louis 8
Falkenstein 7
Hefei 7
Hyderabad 7
Lancaster 7
Lanzhou 7
Loja 7
Tel Aviv 7
Arlington Heights 6
Belize City 6
Guayaquil 6
Iasi 6
Istanbul 6
Nairobi 6
New Delhi 6
Ningbo 6
Ottawa 6
Rio de Janeiro 6
San Francisco 6
Totale 5.652
Salva come PNG Salva come JPEG
Nome #
Myasthenia gravis 209
International consensus guidance for management of myasthenia gravis: Executive summary 203
Single-centre 40-year results of redo operation for recurrent thymomas. 199
Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies 153
Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection. 149
Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. 149
Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy 142
Thymoma in patients with MG: characteristics and long-term outcome 141
Hypoglossal palsy and coeliac disease: an uncommon presentation for a common disease? 141
Poly-autoimmunity in patients with myasthenia gravis: A single-center experience 141
When myasthenia gravis is not all. 140
T cell repertoire in DQ5-positive MuSK-positive myasthenia gravis patients 133
SFEMG: A piece in the diagnostic puzzle of myasthenia 132
Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis. 131
PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data 126
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 118
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 118
Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis 116
A b3 type-thymoma in a 7-year-old child with myasthenia gravis 114
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 114
Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment 113
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders 113
Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. 111
A Genome-wide Association Study of Myasthenia Gravis 111
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 109
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis 108
Anti-AChR-negative myasthenia gravis: clinical and immunological features 105
3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies 100
Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis 98
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis 97
Determinants of cognitive impairment in elderly myasthenia gravis patients 96
The difficulty in confirming clinical diagnosis of Myasthenia Gravis in a seronegative patient: a possible neurophysiological approach 94
Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis 94
Multiple paraneoplastic diseases associated with thymoma. 93
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long-term results in 180 patients. 93
HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. 93
Response to therapy in myasthenia gravis with anti-MuSK antibody 92
Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis. 88
Management challenges in muscle-specific tyrosine kinase myasthenia gravis. 88
BAFF serum levels in myasthenia gravis: effects of therapy 87
Tumour necrosis factor beta gene polymorphisms in myasthenia gravis 86
Ocular palsies in the absence of other neurological or ocular symptoms: analysis of 105 cases 86
Prognostic grading after complete resection for thymic malignancies 86
Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia 86
Reliability of SFEMG in diagnosing myasthenia gravis: Sensitivity and specificity calculated on 100 prospective cases. 85
Diagnostic features and subtyping of thymoma lymph node metastases 85
Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic etiology 85
Immunosuppressive therapies in myasthenia gravis 84
Myasthenia gravis with presynaptic neurophysiological signs: Two case reports and literature review 84
Myasthenia gravis with antibodies to MuSK: an update 83
Comment on "Cutting edge: human CD4-CD8- thymocytes express FOXP3 in the absence of a TCR". 82
Pattern of ocular involvement in myasthenia gravis with MuSK antibodies 82
Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients 82
Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long term results in 180 patients. 80
Guidelines for treatment of autoimmune neuromuscular transmission disorders. 79
Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis 79
Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function 79
Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age? 79
Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients 78
Clinical heterogeneity of seronegative myasthenia gravis 77
Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study 77
Epidemiological evidence for a hereditary contribution to myasthenia gravis: A retrospective cohort study of patients from North America 77
The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy 76
Lower motor neuron involvement in longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies 75
Spontaneous recovery from anti-NMDAR encephalitis 73
EFNS/ENS Guidelines for the treatment of ocular myasthenia. 72
Acquired myasthenia gravis in childhood. 71
Antibody-phenotype correlation in stiff-person syndrome 70
Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. 70
Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis 70
Positive response to therapy in a patient with a seropositive paraneoplastic cerebellar degeneration and an endometrioid carcinoma of the vesicovaginal septum 67
Overcoming challenges in the diagnosis and treatment of myasthenia gravis 67
A practical guide to the recognition and management of myasthenia gravis 66
Early-onset myasthenia gravis: clinical characteristics and response to therapy 65
SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody 65
In sickness and in health: when myasthenia gravis is a conjugal matter 65
Risk of cancer in patients with myasthenia gravis 64
Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis. 64
Course and treatment of myasthenia gravis during pregnancy 63
Imatinib mesylate in thymic epithelial malignancies. 63
Familial autoimmune myasthenia gravis with different pathogenetic antibodies 63
Myasthenia gravis and associated autoimmune diseases 62
Myasthenia gravis during interferon alfa therapy 62
An update on Thymectomy in Myasthenia Gravis 62
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update 62
Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase 61
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis 61
Anti-P110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement 60
Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma 59
Minimal manifestation status and prednisone withdrawal in the MGTX trial 59
Myasthenia gravis with antibodies to MuSK: another step towards solving mistery? 58
The tiles make a puzzle but the single tile is not the puzzle: The need for a global assessment of the patient 58
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. 57
Benefit and danger from immunotherapy in myasthenia gravis 57
Controversies in Ocular Myasthenia Gravis 57
An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients 56
Thymoma recurrences in myasthenia gravis patients 56
Risk factors for tumor occurrence in patients with myasthenia gravis. 55
242nd ENMC International Workshop: Diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1–3 March 2019 55
Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: A genome-wide association study 55
Totale 9.054
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.819
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.819
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020247 0 0 0 0 0 0 0 0 0 0 142 105
2020/2021987 66 105 19 99 135 50 135 28 121 52 143 34
2021/20221.290 111 97 32 69 97 45 34 197 62 78 182 286
2022/20232.629 313 361 205 387 155 311 256 217 273 41 70 40
2023/20241.174 53 318 47 84 46 163 86 74 11 27 132 133
2024/20251.378 54 90 181 60 171 66 72 119 376 172 17 0
Totale 10.603